Effect of a chemotherapeutic drug on the biodistribution of 99mTc- DTPA in Balb/c mice

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 3, 1998, Pages 313-316

  Britto, D M ^a   Gomes, M L ^a   Rodrigues, P C ^a   Paula, E F ^a   Gutfilen, B ^a   Bernardo Filho, M M ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

99mTc DTPA; Drug interaction; Radiopharmaceutical; Therapeutic drug; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; PENTETATE TECHNETIUM TC 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; MICE; MICE, INBRED BALB C; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PENTETATE; TISSUE DISTRIBUTION; VINCRISTINE;

EID: 0032462807     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 99mTechnetium. Arquivos de Biologia e Tecnologia, 33: 811-817, 1990.
2. Saha G.B.: Fundamentals of Nuclear Pharmacy. Springer-Verlag, New York,1984.
3. Hladik III W.B., Saha G.B. and Study K.T. (Editors): Essentials of Nuclear Medicine Science. Williams and Wilkins, Sidney,1987.
4. 99m technetium: a very simple kit. Acta Medica et Biologica, 40: 129-131,1992.
5. Hladik III W.B., Nigg K.K. and Rhodes B.A.: Drug-induced changes in the biologic distribution of radiopharmaceuticals. Seminars in Nuclear Medicine, 9: 184-218, 1982.
6. 99mTc-pertechnetate binding by human serum and tissues. Journal of Nuclear Medicine,14: 149-158.,1973.
7. Rang H.P. and Dale M.M. (Editors): Farmacologia. Guanabara Koogan, Rio de Janeiro, 1991.
8. Ligny C.L., Gelsema W.J., Tji T.G., Huigen Y.M. and Vink H.A.: Bone seeking radiopharmaceuticals. Nuclear Medicine and Biology,17: 161-179,1990.
9. Hung J.C., Ponto J.A. and Hammes R.J.: Radiopharmaceutical-related piffalls and artifacts. Seminars in Nuclear Medicine, Vol XXVI: 208-255, 1996.
10. Hojelse C., Kristensen K., Sampson C.B.: Factors which affect the integrity of radiopharmaceuticals, in Sampson C.B. (ed): Textbook of Radiopharmacy-Theory and Practice,145-151,1994.
11. 99m radiopharmaceuticals. J. Nucl. Med. Technol , 14: 202-205,1986.
12. Anderson -! and Schrier R-VI Clinical use of drugs in patients with kidney and liver disease. USA:WB Saunders Company, 265-275,1981.
13. Waken C.: Inappropriate ADH secretion associated with massive vincristine overdose. Aust. N. Z. J. Med. 5: 266,1975.
14. Winter S.: SIADH secondary to vinblastine overdose. Can. Med. Assoc. 1117:1134, 1977.
15. Pinedo H.A. and Chabner B.A. (Editors): Cancer chemotherapy 7. Elsevier Science Puublishers BV,1985.
16. Mareel M. and De Mets M.: Effect of microtubule inhibitors on invasion and on related activities of tumor cells. Int. Ver. Cytol., 90: 125,1984.
17. Ibrahim E. M., Bunyan R.F., Al-Mulhim F.A., Nabhan M. and Ibrahim R.E.: Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors. Acta Haematol. 6: 126-134,1996.
18. Cooper I.A., Wolf M.M., Robterson T.I., Fox R.M., Mattheus J.P., Stone J.M. Ding J.C., Dart G., Mattheus J., Firkin F.C., Lowenthal R. and Ironside P. (1994): Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J. Clin. Oncol., 2 769-778,1994.
19. Oken M.M., Creech R.H. and Tormey D.C. (1982): Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5 649-655,1982.
20. Costa M.A., Rabinowits M., Froimtchuk M.J., Olivatto L.O., Allan S.E., Gil R.A., Andrade C.A., Martino J.L., Dobbin J.A. and Carrico M.K.: Long-term results with MACOP-B in the treatment of agressive non-Hodgkin's lymphomas. Am. J. Clinl. C)ncol.,17: 323-327,1994.
21. Peterson K., Paleologos N., Forsyth P., MacDonald D.R. and Cairncross G.: Salvage chemotherapy oligodendroglioma. J. Neurosurg., 85: 597-601,1996.
22. Parekh H. and Simpkins H.: Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemothe. Pharmacol., 37: 457-462,1996.
23. Salloum E., Doria R., Schubert W., et al .: Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J. Clin. Oncol., 4 2435-2443,1996.
24. Oguchi M., Izuno I., Takei K., et al.: Treatment for non-Hodgkin's lymphoma (stage 1, 11) of the elderly: usefulness of local and regional irradiation and reduced dose chemmotherapy. Int. J. Radiation. Oncology Biol. Phys., 37 87-92,1997.
25. Baiducci L., Parker M., Sexton W. and Tantranond P.: Pharmacology of antineoplastic agents in the erderly patient. Semin. Oncol.,16: 76-84,1989.
26. Wei J.Y.: Cardiovascular comorbidity in the older cancer patient. Oncol, 22: 9-10,1995.
27. Lipschitz D.A.: Age-related declines in hematopoietic reserve capacity. Semin. Oncol.,22: 3-5,1995.
28. 99m DTPA: Comparison of plasma clearance techniques. J. Nucl. Med., 28: 372-377,1987.
29. Remington R.D. and Schork M.A.: Statistics with applications to the biological and health sciences. Prentice-Hall, Inc. Englewood Cliffs, New Jersey,1985.
30. Hesslewood S. and Leung E.: Drug interactions with radiopharmaceuticals . Eur. J. Nucl. Med., 21: 348-356,1994.